Remote Ischemic Preconditioning for Intracranial Aneurysm Treatment (RIPAT)
Primary Purpose
Cerebral Aneurysm
Status
Unknown status
Phase
Not Applicable
Locations
Austria
Study Type
Interventional
Intervention
Remote ischemic preconditioning
Sham preconditioning
Sponsored by
About this trial
This is an interventional prevention trial for Cerebral Aneurysm focused on measuring neuroprotection, ischemic preconditioning, cerebral aneurysm
Eligibility Criteria
Inclusion Criteria:
- Informed written consent of patient
- Age > 18 years
- Intracranial aneurysm, single or multiple, intervention as indicated by interdisciplinary vascular board (includes previously treated aneurysms)
- Normal baseline MRI
Exclusion Criteria:
- Clinical or radiological signs of subarachnoid hemorrhage
- Planned vessel sacrifice as the primary modality for aneurysm treatment
- Dissecting or mycotic aneurysm
- Previous history of stroke or TIA within the last six months
- Signs or symptoms of upper and lower extremity peripheral vascular illness
- Drugs and lifestyle factors that interfere with biomarker Determination
- Inability to complete neuropsychological testing for language reasons
- Patients unable to have an MRI scan for any reason
- Previous serious cerebral disease that would preclude completion of the protocol or preclude MRI analysis of small strokes
- Pregnancy
Sites / Locations
- Clinical Department of Neurosurgery, Innsbruck Medical UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Sham Comparator
Arm Label
Remote ischemic preconditioning
Sham preconditioning
Arm Description
Inflation of a blood pressure cuff around an arm with the patient under general anesthesia prior to start aneurysm treatment
Sham inflation of a blood pressure cuff around an arm with the patient under general anesthesia prior to start aneurysm treatment
Outcomes
Primary Outcome Measures
Area-under-Curve for biomarkers in the first 5 days after aneurysm treatment(S100B, NSE, GFAP, NSE, MMP9, Microparticles)
Serum biomarkers reflect brain tissue ischemic damage with various specificity and sensitivity (see Whiteley 2008, Ahmad 2012) Advantages include (1) to be available early, (2) to be continuous variables (low study n), (3) they were able to demonstrate an effect of ischemic preconditioning in other clinical studies (see Koch 2010, Veighei 2012)
Secondary Outcome Measures
Number (n) of new lesions in postinterventional MRI (DWI and FLAIR)
Outcome Parameter used in other clinical studies focussing on ischemia after neurointerventional procedures (e.g. ENACT study)
Clinical outcome ( National Institutes of Health Stroke Scale, NIHSS and modified Rankin Scale mRS)
Established outcome parameters for cerebrovascular studies. Dichotomized into favourable (NIHSS ≤1, mRS 0-1) and unfavourable
Volume (mm3) of new lesions in postinterventional MRI (DWI and FLAIR)
As above for number of lesions
Full Information
NCT ID
NCT02162654
First Posted
June 10, 2014
Last Updated
June 11, 2014
Sponsor
Medical University Innsbruck
1. Study Identification
Unique Protocol Identification Number
NCT02162654
Brief Title
Remote Ischemic Preconditioning for Intracranial Aneurysm Treatment
Acronym
RIPAT
Official Title
The Role of Remote Ischemic Preconditioning in the Prevention of Ischemic Brain Damage During Intracranial Aneurysm Treatment (RIPAT) - A Prospective Randomized Exploratory Study
Study Type
Interventional
2. Study Status
Record Verification Date
June 2014
Overall Recruitment Status
Unknown status
Study Start Date
November 2013 (undefined)
Primary Completion Date
November 2015 (Anticipated)
Study Completion Date
November 2016 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical University Innsbruck
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The RIPAT study is a prospective, randomized, double-blind study organized by the neurovascular group of the Clinical Department of Neurosurgery of Innsbruck Medical University, Innsbruck, Austria. Patients aged 18+ in whom the treatment of an un-ruptured intracranial aneurysm is indicated are eligible for study participation. Prior to aneurysm treatment, with the patient already under general anesthesia, the blood supply to an arm will be restricted for 3x 5minutes by inflating a standard blood pressure cuff. The study hypothesis is that this "remote ischemic preconditioning" maneuver is able to prevent a stroke during the following treatment of the aneurysm.
Detailed Description
Prospective, randomized, double-blind, explorative single center clinical trial in patients subjected to the treatment of an un-ruptured intracranial aneurysm, either by surgical clipping or endovascular coiling. Goal of the study is to determine whether remote ischemic preconditioning (RIPC) prior to aneurysm treatment alters various biomarkers associated with ischemic central neuronal tissue damage. The trial takes place at Innsbruck University Hospital of Innsbruck Medical University, Innsbruck, Austria.
Patients fulfilling inclusion criteria are randomly allocated either to pre-interventional ischemic preconditioning (Group A = intervention group) or sham preconditioning (Group B = control group). RIPC is performed by inflating a blood pressure cuff around one upper extremity three times for five minutes with five minutes interval with the patient under general anesthesia prior to the start of the procedure.
Patients, all staff involved in diagnosis and treatment and all study members are blinded to the patients' group affiliation. The anesthesiologist and two staff members who perform preconditioning are not blinded.
Primary outcome is a difference of ± 2SD in the concentration-time curve of a panel of biochemical parameters indicative of cerebral ischemia (S100B, NSE, GFAP, MMP9, MBP, microparticles) in the first five days after the intervention. Secondary outcome parameters are changes in the post-interventional MRI and neuropsychological and clinical outcome at six and 12 months.
CONSORT and TIDieR guidelines will be followed. The trail will be registered in a public database. The trail protocol will be published in an open-access journal.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cerebral Aneurysm
Keywords
neuroprotection, ischemic preconditioning, cerebral aneurysm
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
48 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Remote ischemic preconditioning
Arm Type
Active Comparator
Arm Description
Inflation of a blood pressure cuff around an arm with the patient under general anesthesia prior to start aneurysm treatment
Arm Title
Sham preconditioning
Arm Type
Sham Comparator
Arm Description
Sham inflation of a blood pressure cuff around an arm with the patient under general anesthesia prior to start aneurysm treatment
Intervention Type
Procedure
Intervention Name(s)
Remote ischemic preconditioning
Intervention Description
The blood pressure cuff is inflated to 200 mmHg for 3 x 5 minutes with 5 minutes of reperfusion by complete cuff deflation each.
Intervention Type
Procedure
Intervention Name(s)
Sham preconditioning
Intervention Description
The blood pressure cuff is inflated to 10 mmHg for 3 x 5 minutes with 5 minutes of complete cuff deflation each.
Primary Outcome Measure Information:
Title
Area-under-Curve for biomarkers in the first 5 days after aneurysm treatment(S100B, NSE, GFAP, NSE, MMP9, Microparticles)
Description
Serum biomarkers reflect brain tissue ischemic damage with various specificity and sensitivity (see Whiteley 2008, Ahmad 2012) Advantages include (1) to be available early, (2) to be continuous variables (low study n), (3) they were able to demonstrate an effect of ischemic preconditioning in other clinical studies (see Koch 2010, Veighei 2012)
Time Frame
on admission, after preconditioning but prior to intervention, at completion of intervention, at hours 3, 6, 12, 24, 48, 72, 96, 120 after completion of intervention
Secondary Outcome Measure Information:
Title
Number (n) of new lesions in postinterventional MRI (DWI and FLAIR)
Description
Outcome Parameter used in other clinical studies focussing on ischemia after neurointerventional procedures (e.g. ENACT study)
Time Frame
preinterventional/on day 1 or 2
Title
Clinical outcome ( National Institutes of Health Stroke Scale, NIHSS and modified Rankin Scale mRS)
Description
Established outcome parameters for cerebrovascular studies. Dichotomized into favourable (NIHSS ≤1, mRS 0-1) and unfavourable
Time Frame
at discharge, at 6 and 12 months
Title
Volume (mm3) of new lesions in postinterventional MRI (DWI and FLAIR)
Description
As above for number of lesions
Time Frame
preinterventional, postinterventional on day 1 or 2
Other Pre-specified Outcome Measures:
Title
Neuropsychological testing VLMTA (Verbaler Lern- und Merkfähigkeitstest), the WMS-R (Zahlenspanne vorwärts und rückwärts), trail making A and B tests, the Regensburger Wortflüssigkeitstest, the TAP Wechsel verbal, the TAP and the HADS-D)
Description
Standard tests used in patients with cerebrovascular disorders in our departments. Not applicable to non-german-speaking patients.
Time Frame
preinterventional, at 6 and 12 months
Title
Brain volume changes (MRI, voxel -based morphometry)
Description
Longterm brain volume changes that correlate with NP deficits (Horstmann 2010, Moskowitz 2011, Vuylsteke 2011) will be analyzed using voxel-based morphometry techniques
Time Frame
Preinterventional/at the 12 months FU
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Informed written consent of patient
Age > 18 years
Intracranial aneurysm, single or multiple, intervention as indicated by interdisciplinary vascular board (includes previously treated aneurysms)
Normal baseline MRI
Exclusion Criteria:
Clinical or radiological signs of subarachnoid hemorrhage
Planned vessel sacrifice as the primary modality for aneurysm treatment
Dissecting or mycotic aneurysm
Previous history of stroke or TIA within the last six months
Signs or symptoms of upper and lower extremity peripheral vascular illness
Drugs and lifestyle factors that interfere with biomarker Determination
Inability to complete neuropsychological testing for language reasons
Patients unable to have an MRI scan for any reason
Previous serious cerebral disease that would preclude completion of the protocol or preclude MRI analysis of small strokes
Pregnancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Martin Ortler, M.D., MSc.
Phone
0043-512-504
Ext
80975
Email
martin.ortler@i-med.ac.at
First Name & Middle Initial & Last Name or Official Title & Degree
Claudius Thomé, M.D.
Phone
0043-512-504
Ext
27452
Email
claudius.thome@i-med.ac.at
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Martin Ortler, M.D., MSc.
Organizational Affiliation
Clinical Department of Neurosurgery, Innsbruck Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinical Department of Neurosurgery, Innsbruck Medical University
City
Innsbruck
ZIP/Postal Code
6020
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Ortler, M.D., MSc.
Phone
0043-512-504
Ext
80975
Email
martin.ortler@i-med.ac.at
First Name & Middle Initial & Last Name & Degree
Selma Tülü, Cand. med.
Email
selma.tuelue@student.i-med.ac.at
First Name & Middle Initial & Last Name & Degree
Martin Ortler, MD, MSc
First Name & Middle Initial & Last Name & Degree
Claudius Thomé, M.D.
First Name & Middle Initial & Last Name & Degree
Selma Tülü, Cand.med.
First Name & Middle Initial & Last Name & Degree
Miriam Mulino, M.D.
First Name & Middle Initial & Last Name & Degree
Daniel Pinggera, M.D.
First Name & Middle Initial & Last Name & Degree
Claudia Unterhofer, M.D.
First Name & Middle Initial & Last Name & Degree
Erich Schmutzhard, M.D.
First Name & Middle Initial & Last Name & Degree
Bettina Pfausler, M.D.
First Name & Middle Initial & Last Name & Degree
Ronny Beer, M.D.
First Name & Middle Initial & Last Name & Degree
Raimund Helbok, M.D.
First Name & Middle Initial & Last Name & Degree
Peter Lackner, M.D.
First Name & Middle Initial & Last Name & Degree
Thomas Benke, M.D.
First Name & Middle Initial & Last Name & Degree
Thomas Bodner, M.D.
First Name & Middle Initial & Last Name & Degree
Margarethe Delazer, M.D.
First Name & Middle Initial & Last Name & Degree
Raffaella Matteucci-Gothe, Ph.D.
First Name & Middle Initial & Last Name & Degree
Uwe Siewert, Ph.D.
First Name & Middle Initial & Last Name & Degree
Philipp Würtinger, M.D.
First Name & Middle Initial & Last Name & Degree
Andrea Griesmacher, M.D.
First Name & Middle Initial & Last Name & Degree
Markus Luger, M.D.
First Name & Middle Initial & Last Name & Degree
Arnulf Benzer, M.D.
First Name & Middle Initial & Last Name & Degree
Franz Wiedermann, M.D.
First Name & Middle Initial & Last Name & Degree
Astrid Grams, M.D.
First Name & Middle Initial & Last Name & Degree
Elke Gizewski, M.D.
12. IPD Sharing Statement
Learn more about this trial
Remote Ischemic Preconditioning for Intracranial Aneurysm Treatment
We'll reach out to this number within 24 hrs